Aptorum Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APM.PA research report →
About the company
Aptorum Group Limited is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic products aimed at infectious diseases and various cancers. Its operations are structured across Therapeutics and Non-Therapeutics segments. The company's robust pipeline includes SACT-1 for neuroblastoma and other cancer types; SACT-COV19 for coronavirus disease; ALS-4, designed to combat bacterial infections such as MRSA; and ALS-1 for Influenza A viral infections.
- CEO
- Darren Lui
- IPO
- 2020
- Employees
- 26
- HQ
- London, GB
Price Chart
- Market Cap
- $8.82M
- P/E
- -4.24
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- -2.83
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -5.90%
- ROIC
- -10.36%
- Revenue
- $431.38K · -66.71%
- Net Income
- $-2,824,647 · -272.41%
- EPS
- $-0.62 · 77.45%
- Op Income
- $-9,656,561
- FCF YoY
- 38.21%
- 52W High
- $27.00
- 52W Low
- $2.70
- 50D MA
- $27.00
- 200D MA
- $15.21
- Beta
- -0.07
- Avg Volume
- 0
Get TickerSpark's AI analysis on APM.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our APM.PA coverage
Recent articles, reports, and earnings notes.
No research on APM.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APM.PA report →Similar companies
Peers in the same neighborhood.